- Document Number:
20160374967
- Appl. No:
15/235847
- Application Filed:
August 12, 2016
- نبذة مختصرة :
A method for the prevention or treatment of human immunodeficiency virus infection by administering an effective amount of amifostine, phosphonol, or similar compound to an individual in need is provided.
- Claim:
1.-18. (canceled)
- Claim:
19. A method of treating a human immunodeficiency virus infection in a patient in need thereof, the method comprising: administering to the patient an effective antiretroviral amount of a compound or a pharmaceutically acceptable salt or solvate thereof in a unit dosage form, wherein the compound is of Formula (I) or Formula (II): [chemical expression included] wherein X is selected from the group consisting of hydrogen and a leaving group, wherein each of R1, R2, and R3 is independently selected from hydrogen and C1-6 alkyl, and wherein n is an integer of from 1 to 10; and administering to the patient 300 mg/day or less of at least one nucleoside reverse transcriptase inhibitor.
- Claim:
20. The method of claim 19, wherein the unit dosage form comprises from about 500 mg to about 700 mg of the compound.
- Claim:
21. (canceled)
- Claim:
22. The method of claim 19, wherein said compound of Formula (I) or Formula (II) is administered to the patient in an effective cytoprotective amount.
- Claim:
23. The method of claim 22, wherein the unit dosage form comprises from about 100 mg to about 300 mg of the compound.
- Claim:
24. The method of claim 19, wherein the unit dosage form when administered once yields a peak intracellular concentration of less than 30 nanomolar.
- Claim:
25. The method of claim 19, wherein the compound is of formula (I) and wherein X is H.
- Claim:
26. The method of claim 19, wherein the compound is of formula (II).
- Claim:
27. The method of claim 19, wherein X is a leaving group selected from the group consisting of phosphonate, acetyl, isobutyryl, pivaloyl, benzoyl, C1-6 alkyl, C6-18 aryl, keto substituted C1-6 alkyl, and keto substituted C6-18 aryl.
- Claim:
28. The method of claim 19, wherein the compound is amifostine.
- Claim:
29. The method of claim 19, wherein the compound is phosphonol.
- Claim:
30. The method of claim 19, wherein the compound is [chemical expression included]
- Claim:
31. The unit dosage form of claim 1, wherein the compound is [chemical expression included]
- Claim:
32. The method of claim 19 further comprising: administering a Cu-dependent amine-oxidase blocker.
- Claim:
33. The method of claim 32, wherein the Cu-dependent amine-oxidase blocker is aminoguanidine.
- Claim:
34. The method of claim 19 further comprising: administering a reducing agent selected from the group consisting of vitamin C, vitamin E, glucose, mannose, galactose, xylose, ribose, arabinose, and combinations thereof.
- Claim:
35. The method of claim 19, wherein the compound is a prodrug form, and wherein X is at least a portion of a DNA binding agent or a nucleic acid binding agent tethered to a remaining portion of the compound.
- Claim:
36. The method of claim 35, wherein X is at least a portion of a nucleoside analog.
- Claim:
37. The method of claim 36, wherein the nucleoside analog is selected from the group consisting of zidovudine, lamivudine, didanosine, zaicitabine, stavudine, and abacavir.
- Claim:
38. The method of claim 19, wherein the nucleoside reverse transcriptase inhibitors are selected from the group consisting of zidovudine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, and combinations thereof.
- Claim:
39. The method of claim 38, wherein at least one of the nucleoside reverse transcriptase inhibitors is zidovudine.
- Claim:
40. (canceled)
- Claim:
41. A method of treating a human immunodeficiency virus infection in a patient in need thereof comprising: administering to the patient an effective antiretroviral amount of a compound or a pharmaceutically acceptable salt or solvate thereof in a unit dosage form, wherein the compound is of Formula (I) or Formula (II): [chemical expression included] wherein X is selected from the group consisting of hydrogen and a leaving group, wherein each of R1, R2, and R3 is independently selected from hydrogen and C1-6 alkyl, and wherein n is an integer of from 1 to 10; and administering to the patient a daily dosage of from about 300 mg/day to about 400 mg/day of at least one nucleoside reverse transcriptase inhibitor.
- Claim:
42. The method of claim 41, wherein the at least one nucleoside reverse transcriptase inhibitor is zidovudine.
- Claim:
43. The method of claim 41, wherein the compound is a compound of Formula (I).
- Claim:
44. The method of claim 19, wherein the compound is of Formula (I).
- Current International Class:
61; 61; 61; 61
- الرقم المعرف:
edspap.20160374967
Processing Request
No Comments.